Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 2, June 2020

Volume 14 Issue 2

In this issue...

• The cell & gene therapy market matures

• Wave of collaborations accelerate vaccine development

• Dealmaking in 2020 faces new challenges

Cover image: Gene therapy conceptual illustration; a double stranded DNA (deoxyribonucleic acid) molecule coming out of a viral capsid. Science Photo Library / Alamy Stock Photo

The cell & gene therapy market matures

    Feature

  • News Feature |

    The next-generation therapeutics space has continued to progress on several fronts in the past 12 months, but this could be set to change as the industry copes with the COVID‑19 crisis.

    • Paul Verdin
  • Profiles

  • Advertisement Feature |

    Biotech start-up company NovaGo is developing human antibodies that stimulate nerve repair and regeneration following a stroke. The company’s lead candidate anti-Nogo-A antibody (NG004) is ready for phase 1 trials, and it is looking for partners to develop it through the clinic.

    • NovaGo Therapeutics AG
  • Advertisement Feature |

    Biotech company Cellatoz Therapeutics is developing innovative cell therapies by applying its proprietary cells, known as A-to-Z cells to multiple therapeutic areas. The company is now looking for partners to develop the therapies further.

    • Cellatoz Therapeutics, Inc.
  • Advertisement Feature |

    inRegen’s personalized progenitor cell therapy injects autologous kidney cells (REACT) into patients’ damaged kidneys, where cells migrate and restore kidney function. The cell-based treatment is showing signs of promise in ongoing phase 2 trials.

    • inRegen
  • Advertisement Feature |

    Japanese company Synplogen uses technology based on over a decade of academic research to design and manufacture long and complex sequences of synthetic DNA. The company is also engaged in novel drug discovery and R&D of gene and cell therapies.

    • Synplogen Co., Ltd.
  • Advertisement Feature |

    Novadip is designing new treatment options for critical size defects, complex small size defects and surgically inaccessible tissue with its patented 3D tissue regeneration technology platform to transform the lives of patients with unmet medical needs.

    • Novadip Biosciences
  • Advertisement Feature |

    Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease and β-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning, has provided stable reductions in disease burden and opioid dependence.

    • Aruvant Sciences
  • Advertisement Feature |

    MiCAN Technologies has developed Mylc cells, human myeloid lineage cells for use in the study of infectious diseases caused by viruses. The company is also developing a human red blood-like cell product, Mpv. It is hoped that, together, these products will accelerate vaccine and drug development globally.

    • MiCAN Technologies Inc.

Wave of collaborations accelerate vaccine development

    Feature

  • News Feature |

    History has shown that collaborative efforts can have a crucial role in combating viral outbreaks such as the current coronavirus pandemic.

    • Raveena Bhambra
  • Profiles

  • Advertisement Feature |

    Amicoat’s environmentally friendly antimicrobial coating technology has a broad spectrum of activity with a low risk of provoking antibiotic resistance. The peptide-based technology effectively eliminates biofilms and can be applied to a wide range of medical devices to reduce healthcare-associated infections.

    • Amicoat AS
  • Advertisement Feature |

    Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

    • Sanofi Pasteur
  • Advertisement Feature |

    TAXIS Pharmaceuticals is developing first-in-class anti-resistance drugs to help re-engage widely prescribed but resistance-prone generic antibiotics to treat patients with multidrug-resistant infections. The company is actively looking to partner its lead assets with pharma and to in-license novel anti-resistance drug candidates for development.

    • TAXIS Pharmaceuticals, Inc.
  • Advertisement Feature |

    By acting directly on human cell machinery, Atriva Therapeutics’ lead candidate antiviral ATR-002 combines several advantages over existing therapies and could combat respiratory diseases such as influenza and COVID-19.

    • Atriva Therapeutics GmbH

Dealmaking in 2020 faces new challenges

    Feature

  • Profiles

  • Advertisement Feature |

    D&D Pharmatech funds the development of innovative therapeutic and diagnostic solutions to address critical unmet medical needs. D&D subsidiary Theraly Fibrosis is developing a novel treatment for chronic pancreatitis and other fibrotic indications, TLY012. Neuraly, another D&D subsidiary, recently launched a phase 2 study in Parkinson disease.

    • D&D PharmaTech
  • Advertisement Feature |

    Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome from a novel population of cells derived from the amnion. The biological factors secreted by these cells have unique anti-inflammatory and neuroprotective effects. Presently, the company is looking for partners to drive clinical drug development of its lead product, ST266, in ophthalmic indications.

    • Noveome Biotherapeutics
  • Advertisement Feature |

    Panorama Medicine has built a combined genomics and advanced computational analysis platform to develop therapies for diseases treatable through transcriptome modulation. The company is looking to partner its therapeutic solutions through licensing options, or to collaborate on custom screening projects.

    • Panorama Medicine

Search

Quick links